Adebrelimab
Bronchial Neoplasms
Nanfang Hospital, Southern Medical UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Bronchial Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Vinorelbine University of Turin, Italy | Phase 3 | B |
Docetaxel University of Turin, Italy | Phase 3 | B |
Icotinib Sun Yat-sen University | Phase 2 | B |
ETOPOSIDE Nanfang Hospital, Southern Medical University | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
Adebrelimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →